Assessing Cognitive Function in Adults During or Following Chemotherapy: a Scoping Review

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2016 Apr 13

PMID 27067592

Citations 7

Authors

Karin Olson

Joanne Hewit

Linda G Slater

Thane Chambers

Deborah Hicks

Anna Farmer

Kathryn Grattan

Shawn Steggles

Bryan Kolb

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this scoping review was to determine the feasibility of conducting a systematic review of approaches for screening or assessing cognitive function that were comprehensive and that could be incorporated into clinical settings.

Methods: Using the scoping review approach developed by Arksey and O'Malley, we searched Ovid Embase 1980-, Ovid PsycINFO 1806-, Ovid Health and Psychosocial Instruments 1985-, EBSCOhost CINAHL, ISI Web of Science (Science Citation Index 1900-), Social Sciences Citation Index 1900-, Conference Proceedings Citation Index -Science 1990-, Conference Proceedings Citation Index -Social Science & Humanities 1990-, Scopus 1960-, with no language restrictions. Searches were conducted in April 2009 and updated in February 2013. Studies of adults treated with chemotherapy that included at least seven of the eight domains of cognition were included.

Results: Eleven studies met inclusion criteria. No screening tools suitable for inclusion in a clinic were identified. The studies reviewed varied by inclusion/exclusion criteria, design, and instruments for assessing cognitive function, and thus, there are not yet enough studies to warrant a systematic review on this topic.

Citing Articles

Understanding experiences of cognitive decline and cognitive assessment from the perspectives of people with glioma and their caregivers: A qualitative interview study.

Carlson M, Fradgley E, Paul C Int J Nurs Stud Adv. 2024; 6:100179.

PMID: 38746812 PMC: 11080318. DOI: 10.1016/j.ijnsa.2024.100179.

Acceptability and feasibility of cognitive assessments with adults with primary brain cancer and brain metastasis: A systematic review.

Carlson M, Fradgley E, Yates D, Morris S, Tait J, Paul C Neurooncol Pract. 2023; 10(3):219-237.

PMID: 37188159 PMC: 10180383. DOI: 10.1093/nop/npac097.

Lambert M, Ouimet L, Wan C, Stewart A, Collins B, Vitoroulis I Oncol Rev. 2018; 12(2):371.

PMID: 30294410 PMC: 6170883. DOI: 10.4081/oncol.2018.371.

Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice.

Kovalchuk A, Ilnytskyy Y, Rodriguez-Juarez R, Katz A, Sidransky D, Kolb B Oncotarget. 2017; 8(51):88276-88293.

PMID: 29179434 PMC: 5687604. DOI: 10.18632/oncotarget.19835.

Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice.

Kovalchuk A, Ilnytskyy Y, Rodriguez-Juarez R, Shpyleva S, Melnyk S, Pogribny I Aging (Albany NY). 2017; 9(7):1660-1676.

PMID: 28758896 PMC: 5559168. DOI: 10.18632/aging.101243.

References

Asher A . Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil. 2011; 90(5 Suppl 1):S16-26. DOI: 10.1097/PHM.0b013e31820be463. View

Collins B, MacKenzie J, Stewart A, Bielajew C, Verma S . Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2008; 18(2):134-43. DOI: 10.1002/pon.1379. View

Tager F, McKinley P, Schnabel F, El-Tamer M, Cheung Y, Fang Y . The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2009; 123(1):25-34. DOI: 10.1007/s10549-009-0606-8. View

Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E . A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006; 20(1):76-89. DOI: 10.1080/138540491005875. View

de Ruiter M, Reneman L, Boogerd W, Veltman D, van Dam F, Nederveen A . Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2010; 32(8):1206-19. PMC: 6869999. DOI: 10.1002/hbm.21102. View

Lawlor P . The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer. 2002; 94(6):1836-53. DOI: 10.1002/cncr.10389. View

Meyers C, Wefel J . The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003; 21(19):3557-8. DOI: 10.1200/JCO.2003.07.080. View

Nieuwenhuijsen K, de Boer A, Spelten E, Sprangers M, Verbeek J . The role of neuropsychological functioning in cancer survivors' return to work one year after diagnosis. Psychooncology. 2008; 18(6):589-97. DOI: 10.1002/pon.1439. View

Ouimet L, Stewart A, Collins B, Schindler D, Bielajew C . Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2008; 31(1):73-89. DOI: 10.1080/13803390801992725. View

10.

Schagen S, Muller M, Boogerd W, Rosenbrand R, van Rhijn D, Rodenhuis S . Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13(9):1387-97. DOI: 10.1093/annonc/mdf241. View

11.

Schagen S, van Dam F, Muller M, Boogerd W, Lindeboom J, Bruning P . Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85(3):640-50. DOI: 10.1002/(sici)1097-0142(19990201)85:3<640::aid-cncr14>3.0.co;2-g. View

12.

Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux M, Munzel K . Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008; 113(9):2431-9. DOI: 10.1002/cncr.23853. View

13.

Jansen C, Cooper B, Dodd M, Miaskowski C . A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2010; 19(10):1647-56. DOI: 10.1007/s00520-010-0997-4. View

14.

Vardy J, Wong K, Yi Q, Park A, Maruff P, Wagner L . Assessing cognitive function in cancer patients. Support Care Cancer. 2006; 14(11):1111-8. DOI: 10.1007/s00520-006-0037-6. View

15.

Downie F, Mar Fan H, Houede-Tchen N, Yi Q, Tannock I . Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006; 15(10):921-30. DOI: 10.1002/pon.1035. View

16.

Hutchinson A, Hosking J, Kichenadasse G, Mattiske J, Wilson C . Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012; 38(7):926-34. DOI: 10.1016/j.ctrv.2012.05.002. View

17.

Bender C, Sereika S, Berga S, Vogel V, Brufsky A, Paraska K . Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2005; 15(5):422-30. DOI: 10.1002/pon.964. View

18.

Raffa R, Duong P, Finney J, Garber D, Lam L, Mathew S . Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?. J Clin Pharm Ther. 2006; 31(2):129-38. DOI: 10.1111/j.1365-2710.2006.00726.x. View

19.

Vardy J, Rourke S, Tannock I . Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007; 25(17):2455-63. DOI: 10.1200/JCO.2006.08.1604. View

20.

Palmateer L, McCartney J . Do nurses know when patients have cognitive deficits?. J Gerontol Nurs. 1985; 11(2):6-7, 10-2, 15-6. DOI: 10.3928/0098-9134-19850201-05. View